Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer
โ Scribed by Kevin C. De Braganca; Yelena Y. Janjigian; Christopher G. Azzoli; Mark G. Kris; Maria C. Pietanza; Craig P. Nolan; Antonio M. Omuro; Andrei I. Holodny; Andrew B. Lassman
- Publisher
- Springer US
- Year
- 2010
- Tongue
- English
- Weight
- 208 KB
- Volume
- 100
- Category
- Article
- ISSN
- 0167-594X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Brain is the most common site of metastatic spread in small-cell lung cancer (SCLC). Approximately 10% of SCLC patients have brain metastases (BM) already at diagnosis and an additional 40% will develop central nervous system (CNS) involvement during their disease course. Although whole brain radiot
In the current study the relationship between the incidence of metastatic spread and expression (at the protein level) of various proto-oncogenes was investigated in 217 human non-small cell lung carcinomas. Tumors with an overexpression of proteins encoded by the oncogenes c-jun and c-myc showed a
## Abstract ## BACKGROUND The aims of this study were to show 1) the effect of changing from computed tomography (CT) to magnetic resonance imaging (MRI) on the prevalence of detected brain metastases (BM) in patients with newly diagnosed small cell lung cancer (SCLC); 2) the difference in surviva